Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands
Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands.
J Clin Microbiol. 2021 Feb 18;59(3). doi: 10.1128/JCM.02278-20.
The aim of this study was to describe the frequency of positive tests in COVID-19 patients and investigate the association between COVID-19 and a positive test result. We compared the proportion of positive tests in COVID-19 patients admitted to the intensive care unit (ICU) for >24 h with two control groups: patients with community-acquired pneumonia with (i) a PCR-confirmed influenza infection (considered a positive control since the link between influenza and invasive aspergillosis has been established) and (ii) pneumonia (in whom positive tests are mostly considered as colonization). During the study period, 92 COVID-19 patients (mean [standard deviation] age, 62 [14] years; 76.1% males), 48 influenza patients (55 [14]; 56.2% males), and 65 pneumococcal pneumonia patients (58 [15], 63,1% males) were identified. Any positive test from any respiratory sample was found in 10.9% of the COVID-19 patients, 6.2% of the patients with pneumococcal pneumonia, and 22.9% of those infected with influenza. A positive culture or PCR or galactomannan test on bronchoalveolar lavage (BAL) fluid only was found in 5.4% of COVID-19 patients, which was lower than in patients with influenza (18.8%) and comparable to that in the pneumococcal pneumonia group (4.6%). Using logistic regression analysis, the odds ratio (OR) (95% confidence interval) for a positive test on BAL fluid for COVID-19 patients was 1.2 (0.3 to 5.1; = 0.8) compared to the pneumococcal pneumonia group, while it was 0.2 (0.1 to 0.8; = 0.02) compared to the influenza group. This difference remained significant when corrected for age and sex. In conclusion, in COVID-19 patients, the prevalence of a positive test was comparable to that in patients admitted for pneumococcal pneumonia but substantially lower than what we observed in patients with influenza.
本研究旨在描述 COVID-19 患者中阳性 检测的频率,并探讨 COVID-19 与 阳性检测结果之间的关联。我们将 COVID-19 患者中入住重症监护病房(ICU)超过 24 小时的患者与两个对照组进行比较:(i)经 PCR 确诊流感感染的社区获得性肺炎患者(考虑到流感与侵袭性曲霉菌病之间的联系已得到证实,因此将其视为阳性对照)和(ii)肺炎患者(在这些患者中, 阳性检测结果主要被认为是定植)。在研究期间,共确定了 92 例 COVID-19 患者(平均[标准差]年龄 62[14]岁;76.1%为男性)、48 例流感患者(55[14]岁;56.2%为男性)和 65 例肺炎链球菌性肺炎患者(58[15]岁;63.1%为男性)。从任何呼吸道样本中检测到任何阳性 检测结果的 COVID-19 患者占 10.9%,肺炎链球菌性肺炎患者占 6.2%,感染流感的患者占 22.9%。仅在 COVID-19 患者的支气管肺泡灌洗液(BAL)中发现阳性培养物或 PCR 或半乳甘露聚糖检测的患者占 5.4%,低于流感患者(18.8%),与肺炎链球菌性肺炎组相当(4.6%)。使用逻辑回归分析,COVID-19 患者 BAL 液阳性 检测的优势比(OR)(95%置信区间)与肺炎链球菌性肺炎组相比为 1.2(0.3 至 5.1;=0.8),与流感组相比为 0.2(0.1 至 0.8;=0.02)。当校正年龄和性别后,这种差异仍然显著。总之,在 COVID-19 患者中,阳性 检测的患病率与肺炎链球菌性肺炎患者相当,但明显低于流感患者。